Sunita Mulpuru
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sunita Mulpuru has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Melanie Chin
Division of Respirology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
4 shared publications- Alan J. Forster
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
3 shared publications - Melanie Chin
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
3 shared publications Melissa K. Andrew
Department of Medicine (Geriatrics), Dalhousie University, Halifax, Nova Scotia, Canada
3 shared publications- Smita Pakhale
The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
3 shared publications - Tetyana Kendzerska
28Ottawa Hospital Sleep Center, The Ottawa Hospital, Ottawa, Canada
3 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (9) , 1349-1359
Evaluating the Role of Inpatient Sleep Studies in Hospitalized Adults in Relation to One-Year Mortality and Healthcare Utilization: A Population-Based Cohort Study
Sleep-disordered breathing (SDB) is common among hospitalized individuals and may contribute to increased health utilization and mortality after discharge, yet the optimal timing and setting for sleep testing remain unclear. We compared one-year healthcare utilization and mortality among hospitalized individuals undergoing (i) inpatient polysomnography (PSG), (ii) delayed post-discharge PSG within one month of discharge (primary analysis), or (iii) no PSG during hospitalization or within one year after discharge (matched non-PSG controls); secondary analyses examined delayed PSG completed within three and six months post-discharge. We conducted a retrospective province-based study using health administrative databases on all adults aged ≥ 18 years (Ontario, Canada), hospitalized between 2012 and 2018, and followed until the earliest of death, loss to follow-up, or December 31, 2019. Outcomes within one year after hospitalization included all-cause death and healthcare costs. To balance baseline characteristics across study groups, we used overlap propensity score weighting to create similar weighted populations for pairwise comparisons. We identified 748 individuals in the inpatient PSG group, 9,310 in the delayed PSG group, and 7,480 in the matched non-PSG controls by exact age, sex, health region and calendar year to the inpatient PSG group. In weighted populations, compared to delayed PSG (within the first month), inpatient PSG group was associated with increased one-year mortality (HR: 2.18, 95% CI: 1.68–2.82) and higher cost (Ratio of Means (RoM): 1.82, 95% CI: 1.64–2.03). Compared to non-PSG controls, inpatient PSG was associated with decreased mortality (HR: 0.72, 95% CI: 0.55–0.94) and higher cost (RoM: 1.73, 95% CI: 1.50–1.99). In the secondary analyses, delayed PSG, compared to non-PSG controls, was associated with lower cost when conducted within 3 and 6 months, but not within one month. In this population-based study of propensity score-weighted hospitalized individuals, inpatient PSG was associated with higher mortality and costs compared to delayed PSG, and with lower mortality, but greater resource use than non-PSG controls. Although weighting reduced measured differences, unmeasured clinical complexity may still influence these associations. Among hospitalized individuals with suspected SDB, delaying PSG until after discharge may achieve similar or better outcomes at lower cost, warranting confirmation in prospective studies.
- 16 March 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (9) , 1349-1359
Open AccessEvaluating the Role of Inpatient Sleep Studies in Hospitalized Adults in Relation to One-Year Mortality and Healthcare Utilization: A Population-Based Cohort Study
Sleep-disordered breathing (SDB) is common among hospitalized individuals and may contribute to increased health utilization and mortality after discharge, yet the optimal timing and setting for sleep testing remain unclear. We compared one-year healthcare utilization and mortality among hospitalized individuals undergoing (i) inpatient polysomnography (PSG), (ii) delayed post-discharge PSG within one month of discharge (primary analysis), or (iii) no PSG during hospitalization or within one year after discharge (matched non-PSG controls); secondary analyses examined delayed PSG completed within three and six months post-discharge. We conducted a retrospective province-based study using health administrative databases on all adults aged ≥ 18 years (Ontario, Canada), hospitalized between 2012 and 2018, and followed until the earliest of death, loss to follow-up, or December 31, 2019. Outcomes within one year after hospitalization included all-cause death and healthcare costs. To balance baseline characteristics across study groups, we used overlap propensity score weighting to create similar weighted populations for pairwise comparisons. We identified 748 individuals in the inpatient PSG group, 9,310 in the delayed PSG group, and 7,480 in the matched non-PSG controls by exact age, sex, health region and calendar year to the inpatient PSG group. In weighted populations, compared to delayed PSG (within the first month), inpatient PSG group was associated with increased one-year mortality (HR: 2.18, 95% CI: 1.68–2.82) and higher cost (Ratio of Means (RoM): 1.82, 95% CI: 1.64–2.03). Compared to non-PSG controls, inpatient PSG was associated with decreased mortality (HR: 0.72, 95% CI: 0.55–0.94) and higher cost (RoM: 1.73, 95% CI: 1.50–1.99). In the secondary analyses, delayed PSG, compared to non-PSG controls, was associated with lower cost when conducted within 3 and 6 months, but not within one month. In this population-based study of propensity score-weighted hospitalized individuals, inpatient PSG was associated with higher mortality and costs compared to delayed PSG, and with lower mortality, but greater resource use than non-PSG controls. Although weighting reduced measured differences, unmeasured clinical complexity may still influence these associations. Among hospitalized individuals with suspected SDB, delaying PSG until after discharge may achieve similar or better outcomes at lower cost, warranting confirmation in prospective studies.
- Open Access
- 1 July 2025
- Published by BMJ in BMJ Open Quality
- Vol. 14 (3) , e003366
Pilot study evaluating frailty-focused care for hospitalised patients with chronic obstructive pulmonary disease
Background: Frailty is associated with morbidity and mortality among people with chronic obstructive pulmonary disease (COPD), yet there are no established care pathways to manage frail patients with COPD. To address this gap, we developed, implemented and assessed the feasibility of a new frailty-focused care model for patients hospitalised with exacerbations of COPD. Methods: We conducted a prospective cohort study among hospitalised patients with acute exacerbations of COPD in an academic hospital in Canada over 18 months. We developed and implemented a frailty-focused care model using the degree of frailty to guide personalised assessments, education, and care interventions during and after hospital discharge. We assessed the feasibility of using frailty-focused care in a real-world setting with prespecified targets for recruitment rate, care model completion and collection of patient-reported outcomes including symptom burden, health confidence, health status and self-management scores. Patients were followed up at 3 months after hospitalisation to reassess patient-reported outcomes. Results: 87 patients used the frailty-focused care model during hospitalisation, 58 consented to participate in this study and 45 (78%) completed 3-month postdischarge follow-up. 47% (n=21) were at least mildly frail at baseline, with 35% (n=20) at risk of frailty. Target recruitment of 50 patients was achieved, and all participants completed core elements of frailty-focused care, including frailty assessment, personalised education and discharge planning. Patient-reported outcomes were measured in all participants in hospital, and in 78% (n=45) patients at 3-month follow-up. 23% (n=13) of patients initially reported feeling confident to manage their health condition. This improved to 62% (n=28) at 3-month follow-up. Conclusions: This study provides a foundation to build innovative care models for frail individuals with COPD and shows it is feasible to use frailty-focused care in a real-world hospital setting. Future work requires strong patient engagement to better align frailty-focused care with patient-centred goals.
- 1 July 2025
- Published by BMJ in BMJ Open Quality
- Vol. 14 (3) , e003366
Open AccessPilot study evaluating frailty-focused care for hospitalised patients with chronic obstructive pulmonary disease
Background: Frailty is associated with morbidity and mortality among people with chronic obstructive pulmonary disease (COPD), yet there are no established care pathways to manage frail patients with COPD. To address this gap, we developed, implemented and assessed the feasibility of a new frailty-focused care model for patients hospitalised with exacerbations of COPD. Methods: We conducted a prospective cohort study among hospitalised patients with acute exacerbations of COPD in an academic hospital in Canada over 18 months. We developed and implemented a frailty-focused care model using the degree of frailty to guide personalised assessments, education, and care interventions during and after hospital discharge. We assessed the feasibility of using frailty-focused care in a real-world setting with prespecified targets for recruitment rate, care model completion and collection of patient-reported outcomes including symptom burden, health confidence, health status and self-management scores. Patients were followed up at 3 months after hospitalisation to reassess patient-reported outcomes. Results: 87 patients used the frailty-focused care model during hospitalisation, 58 consented to participate in this study and 45 (78%) completed 3-month postdischarge follow-up. 47% (n=21) were at least mildly frail at baseline, with 35% (n=20) at risk of frailty. Target recruitment of 50 patients was achieved, and all participants completed core elements of frailty-focused care, including frailty assessment, personalised education and discharge planning. Patient-reported outcomes were measured in all participants in hospital, and in 78% (n=45) patients at 3-month follow-up. 23% (n=13) of patients initially reported feeling confident to manage their health condition. This improved to 62% (n=28) at 3-month follow-up. Conclusions: This study provides a foundation to build innovative care models for frail individuals with COPD and shows it is feasible to use frailty-focused care in a real-world hospital setting. Future work requires strong patient engagement to better align frailty-focused care with patient-centred goals.
- Open Access
- 31 March 2025
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 1-12
The impact of frailty on clinical outcomes among individuals with COPD: a systematic review and meta-analysis
Frailty is a prevalent and robust predictor of poor outcomes for older adults and those with chronic disease. We performed a systematic review and meta-analysis of the literature to understand the association between frailty and clinical outcomes for people with COPD. We searched MEDLINE, EMBASE, Cochrane Central, CINAHL, and Web of Science from inception to February 2022, for observational studies evaluating the association between frailty and clinical outcomes among individuals with COPD. Included studies defined COPD by spirometry, used a validated frailty assessment tool, and compared dyspnea, symptom burden, health related quality of life, exacerbations, hospitalization, or mortality between frail and non-frail individuals. Risk of bias was assessed using the Newcastle Ottawa Scale. Mean differences or hazard ratios were calculated using inverse variance (IV) methods, odds ratios were calculated using Mantel–Haenszel methods, and homogeneity was assessed using I 2 statistics. Results were pooled using a random effects model. Of 1385 identified studies, 16 studies were included with 7 studies included in the meta-analyses, representing 5903 individuals. The Fried Frailty Phenotype instrument was used in 50% of included studies. When comparing frail vs. non-frail people with COPD, pooled estimates revealed frail people with COPD had higher dyspnea scores [modified Medical Research Council (mMRC) score standardized mean difference (95% CI): 1.67 (1.40–1.92), I 2 = 24%]; higher symptom burden [COPD Assessment Test (CAT) score mean difference (95% CI): 10.24 (8.30–12.17), I 2 = 31%]; more COPD exacerbations in the prior year [mean difference (95% CI): 1.09 (0.62–1.56), I 2 = 0%), and increased odds of being hospitalized in the previous year [OR (95% CI): 2.94 (1.57–5.50); I 2 = 0%]. The largest study with longest follow up period showed increased mortality risk among frail vs. non-frail individuals with COPD, [HR (95% CI): 1.83 (1.24–2.68)]. People with COPD and frailty experience increased dyspnea, symptom burden, exacerbation history, and hospitalizations compared to non-frail patients with COPD. Frailty is a robust predictor of outcomes among people with COPD and should be considered a treatable trait. Additional work is needed to standardize screening methods for frailty, and to understand the optimal timing of non-pharmacologic interventions to treat frailty among people with COPD. CRD42022329893
- 31 March 2025
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 1-12
Open AccessThe impact of frailty on clinical outcomes among individuals with COPD: a systematic review and meta-analysis
Frailty is a prevalent and robust predictor of poor outcomes for older adults and those with chronic disease. We performed a systematic review and meta-analysis of the literature to understand the association between frailty and clinical outcomes for people with COPD. We searched MEDLINE, EMBASE, Cochrane Central, CINAHL, and Web of Science from inception to February 2022, for observational studies evaluating the association between frailty and clinical outcomes among individuals with COPD. Included studies defined COPD by spirometry, used a validated frailty assessment tool, and compared dyspnea, symptom burden, health related quality of life, exacerbations, hospitalization, or mortality between frail and non-frail individuals. Risk of bias was assessed using the Newcastle Ottawa Scale. Mean differences or hazard ratios were calculated using inverse variance (IV) methods, odds ratios were calculated using Mantel–Haenszel methods, and homogeneity was assessed using I 2 statistics. Results were pooled using a random effects model. Of 1385 identified studies, 16 studies were included with 7 studies included in the meta-analyses, representing 5903 individuals. The Fried Frailty Phenotype instrument was used in 50% of included studies. When comparing frail vs. non-frail people with COPD, pooled estimates revealed frail people with COPD had higher dyspnea scores [modified Medical Research Council (mMRC) score standardized mean difference (95% CI): 1.67 (1.40–1.92), I 2 = 24%]; higher symptom burden [COPD Assessment Test (CAT) score mean difference (95% CI): 10.24 (8.30–12.17), I 2 = 31%]; more COPD exacerbations in the prior year [mean difference (95% CI): 1.09 (0.62–1.56), I 2 = 0%), and increased odds of being hospitalized in the previous year [OR (95% CI): 2.94 (1.57–5.50); I 2 = 0%]. The largest study with longest follow up period showed increased mortality risk among frail vs. non-frail individuals with COPD, [HR (95% CI): 1.83 (1.24–2.68)]. People with COPD and frailty experience increased dyspnea, symptom burden, exacerbation history, and hospitalizations compared to non-frail patients with COPD. Frailty is a robust predictor of outcomes among people with COPD and should be considered a treatable trait. Additional work is needed to standardize screening methods for frailty, and to understand the optimal timing of non-pharmacologic interventions to treat frailty among people with COPD. CRD42022329893
- 1 February 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (2) , e2253692
Comparing the Hospital Frailty Risk Score and the Clinical Frailty Scale Among Older Adults With Chronic Obstructive Pulmonary Disease Exacerbation
Frailty is a multidimensional syndrome characterized by progressive physiologic decline that leads to increased vulnerability to health stressors and acute illness.1,2 It can be conceptualized and objectively measured on a continuum from well to severely frail. Progressive degrees of frailty are associated with increased risks of death, need for institutional care, increased health care costs, and reduced quality of life.2-5 As individuals with chronic disease live longer, assessing and improving frailty and its consequences among patients with chronic diseases is arguably the most pressing issue facing health systems globally.6-8
- 1 February 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (2) , e2253692
Comparing the Hospital Frailty Risk Score and the Clinical Frailty Scale Among Older Adults With Chronic Obstructive Pulmonary Disease Exacerbation
Frailty is a multidimensional syndrome characterized by progressive physiologic decline that leads to increased vulnerability to health stressors and acute illness.1,2 It can be conceptualized and objectively measured on a continuum from well to severely frail. Progressive degrees of frailty are associated with increased risks of death, need for institutional care, increased health care costs, and reduced quality of life.2-5 As individuals with chronic disease live longer, assessing and improving frailty and its consequences among patients with chronic diseases is arguably the most pressing issue facing health systems globally.6-8
- Open Access
- 7 September 2022
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 16 (6) , 1172-1182
Impact of respiratory viral infections on mortality and critical illness among hospitalized patients with chronic obstructive pulmonary disease
Background: Seasonal respiratory viral infections are associated with exacerbations and morbidity among patients with COPD. The real‐world clinical outcomes associated with seasonal viral infections are less well established among hospitalized patients.Research Question: To estimate the association between seasonal respiratory viral infections, 30‐day mortality, and intensive care unit (ICU) admission among hospitalized COPD patients.Study Design and Methods: We conducted an analysis of a national prospective multicenter cohort of COPD patients hospitalized with acute respiratory illness during winter seasons (2011–2015) in Canada. Nasopharyngeal swabs were performed on all patients at the onset of hospital admission for diagnosis of viral infection. Primary outcomes were 30‐day mortality and ICU admissions. Secondary outcomes included invasive/non‐invasive ventilation use.Results: Among 3931 hospitalized patients with COPD, 28.5% (1122/3931) were diagnosed with seasonal respiratory viral infection. Viral infection was associated with increased admission to ICU (OR 1.5, 95% CI 1.2–1.9) and need for mechanical ventilation (OR 1.9, 95% CI 1.4–2.5), but was not associated with mortality (OR 1.1, 95% CI 0.8–1.4). Patients with respiratory syncytial virus (RSV) were equally likely to require ICU admission (OR 1.09, 95% CI 0.67–1.78), and more likely to need non‐invasive ventilation (OR 3.1; 95% CI 1.8–5.1) compared to patients with influenza.Interpretation: Our results suggest COPD patients requiring hospitalization for respiratory symptoms should routinely receive viral testing at admission, especially for RSV and influenza, to inform prognosis, clinical management, and infection control practices during winter seasons. Patients with COPD will be an important target population for newly developed RSV therapeutics.Clinical Trial Registration: ClinicalTrials.gov ID: NCT01517191.
- 7 September 2022
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 16 (6) , 1172-1182
Open AccessImpact of respiratory viral infections on mortality and critical illness among hospitalized patients with chronic obstructive pulmonary disease
Background: Seasonal respiratory viral infections are associated with exacerbations and morbidity among patients with COPD. The real‐world clinical outcomes associated with seasonal viral infections are less well established among hospitalized patients.Research Question: To estimate the association between seasonal respiratory viral infections, 30‐day mortality, and intensive care unit (ICU) admission among hospitalized COPD patients.Study Design and Methods: We conducted an analysis of a national prospective multicenter cohort of COPD patients hospitalized with acute respiratory illness during winter seasons (2011–2015) in Canada. Nasopharyngeal swabs were performed on all patients at the onset of hospital admission for diagnosis of viral infection. Primary outcomes were 30‐day mortality and ICU admissions. Secondary outcomes included invasive/non‐invasive ventilation use.Results: Among 3931 hospitalized patients with COPD, 28.5% (1122/3931) were diagnosed with seasonal respiratory viral infection. Viral infection was associated with increased admission to ICU (OR 1.5, 95% CI 1.2–1.9) and need for mechanical ventilation (OR 1.9, 95% CI 1.4–2.5), but was not associated with mortality (OR 1.1, 95% CI 0.8–1.4). Patients with respiratory syncytial virus (RSV) were equally likely to require ICU admission (OR 1.09, 95% CI 0.67–1.78), and more likely to need non‐invasive ventilation (OR 3.1; 95% CI 1.8–5.1) compared to patients with influenza.Interpretation: Our results suggest COPD patients requiring hospitalization for respiratory symptoms should routinely receive viral testing at admission, especially for RSV and influenza, to inform prognosis, clinical management, and infection control practices during winter seasons. Patients with COPD will be an important target population for newly developed RSV therapeutics.Clinical Trial Registration: ClinicalTrials.gov ID: NCT01517191.
- Open Access
- 5 August 2022
- Published by BMJ in BMJ Open Quality
- Vol. 11 (3) , e001935
Development and assessment of an educational intervention to improve the recognition of frailty on an acute care respiratory ward
Background Frailty is a robust predictor of poor outcomes among patients with chronic obstructive pulmonary disease yet is not measured in routine practice. We determined barriers and facilitators to measuring frailty in a hospital setting, designed and implemented a frailty-focused education intervention, and measured accuracy of frailty screening before and after education. Methods We conducted a pilot cross-sectional mixed-methods study on an inpatient respiratory ward over 6 months. We recruited registered nurses (RNs) with experience using the Clinical Frailty Scale (CFS). RNs evaluated 10 clinical vignettes and assigned a frailty score using the CFS. A structured frailty-focused education intervention was delivered to small groups. RNs reassigned frailty scores to vignettes 1 week after education. Outcomes included barriers and facilitators to assessing frailty in hospital, and percent agreement of CFS scores between RNs and a gold standard (determined by geriatricians) before and after education. Results Among 26 RNs, the median (IQR) duration of experience using the CFS was 1.5 (1–4) months. Barriers to assessing frailty included the lack of clinical directives to measure frailty and large acute workloads. Having collateral history from family members was the strongest perceived facilitator for frailty assessment. The median (IQR) percent agreement with the gold-standard frailty score across all cases was 55.8% (47.2%–60.6%) prior to the educational intervention, and 57.2% (44.1%–70.2%) afterwards. The largest increase in agreement occurred in the ‘mildly frail’ category, 65.4%–81% agreement. Conclusions Barriers to assessing frailty in the hospital setting are external to the measurement tool itself. Accuracy of frailty assessment among acute care RNs was low, and frailty-focused rater training may improve accuracy. Subsequent work should focus on health system approaches to empower health providers to assess frailty, and on testing the effectiveness of frailty-focused education in large real-world settings.
- 5 August 2022
- Published by BMJ in BMJ Open Quality
- Vol. 11 (3) , e001935
Open AccessDevelopment and assessment of an educational intervention to improve the recognition of frailty on an acute care respiratory ward
Background Frailty is a robust predictor of poor outcomes among patients with chronic obstructive pulmonary disease yet is not measured in routine practice. We determined barriers and facilitators to measuring frailty in a hospital setting, designed and implemented a frailty-focused education intervention, and measured accuracy of frailty screening before and after education. Methods We conducted a pilot cross-sectional mixed-methods study on an inpatient respiratory ward over 6 months. We recruited registered nurses (RNs) with experience using the Clinical Frailty Scale (CFS). RNs evaluated 10 clinical vignettes and assigned a frailty score using the CFS. A structured frailty-focused education intervention was delivered to small groups. RNs reassigned frailty scores to vignettes 1 week after education. Outcomes included barriers and facilitators to assessing frailty in hospital, and percent agreement of CFS scores between RNs and a gold standard (determined by geriatricians) before and after education. Results Among 26 RNs, the median (IQR) duration of experience using the CFS was 1.5 (1–4) months. Barriers to assessing frailty included the lack of clinical directives to measure frailty and large acute workloads. Having collateral history from family members was the strongest perceived facilitator for frailty assessment. The median (IQR) percent agreement with the gold-standard frailty score across all cases was 55.8% (47.2%–60.6%) prior to the educational intervention, and 57.2% (44.1%–70.2%) afterwards. The largest increase in agreement occurred in the ‘mildly frail’ category, 65.4%–81% agreement. Conclusions Barriers to assessing frailty in the hospital setting are external to the measurement tool itself. Accuracy of frailty assessment among acute care RNs was low, and frailty-focused rater training may improve accuracy. Subsequent work should focus on health system approaches to empower health providers to assess frailty, and on testing the effectiveness of frailty-focused education in large real-world settings.
- Open Access
- 1 December 2021
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 3275-3284
A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD
Background: Observational studies suggest that immunoglobulin treatment may reduce the frequency of acute exacerbations of COPD (AECOPD). Objective: To inform the design of a future randomised control trial (RCT) of intravenous immunoglobulin (IVIG) treatment efficacy for AECOPD prevention. Methods: A pilot RCT was conducted. We recruited patients with COPD hospitalized for AECOPD, or from ambulatory clinics with one severe, or two moderate AECOPD in the previous year regardless of their serum IgG level. Patients were allocated in a 1:1 ratio with balanced randomisation to monthly IVIG or normal saline for 1 year. The primary outcome was feasibility defined as pre-specified accrual, adherence, and follow-up rates. Secondary outcomes included safety, tolerance, AECOPD rates, time to first AECOPD, quality of life, and healthcare costs. Results: Seventy patients were randomized (37 female; mean age 67.7; mean FEV1 35.1%). Recruitment averaged 4.5± 0.9 patients per month (range 0– 8), 34 (49%) adhered to at least 80% of planned treatments, and four (5.7%) were lost to follow-up. There were 35 serious adverse events including seven deaths and one thromboembolism. None was related to IVIG. There were 56 and 48 moderate and severe AECOPD in the IVIG vs control groups. In patients with at least 80% treatment adherence, median time to first moderate or severe AECOPD was 275 vs 114 days, favoring the IVIG group (HR 0.76, 95% CI 0.3– 1.92). Conclusion: The study met feasibility criteria for recruitment and retention, but adherence was low. A trend toward more robust treatment efficacy in adherent patients supports further study, but future trials must address treatment adherence. Trial registration number: NCT0290038, registered 24 February 2016, https://clinicaltrials.gov/ct2/show/NCT02690038 and NCT03018652, registered January 12, 2017, https://clinicaltrials.gov/ct2/show/NCT03018652.
- 1 December 2021
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 16, 3275-3284
Open AccessA Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD
Background: Observational studies suggest that immunoglobulin treatment may reduce the frequency of acute exacerbations of COPD (AECOPD). Objective: To inform the design of a future randomised control trial (RCT) of intravenous immunoglobulin (IVIG) treatment efficacy for AECOPD prevention. Methods: A pilot RCT was conducted. We recruited patients with COPD hospitalized for AECOPD, or from ambulatory clinics with one severe, or two moderate AECOPD in the previous year regardless of their serum IgG level. Patients were allocated in a 1:1 ratio with balanced randomisation to monthly IVIG or normal saline for 1 year. The primary outcome was feasibility defined as pre-specified accrual, adherence, and follow-up rates. Secondary outcomes included safety, tolerance, AECOPD rates, time to first AECOPD, quality of life, and healthcare costs. Results: Seventy patients were randomized (37 female; mean age 67.7; mean FEV1 35.1%). Recruitment averaged 4.5± 0.9 patients per month (range 0– 8), 34 (49%) adhered to at least 80% of planned treatments, and four (5.7%) were lost to follow-up. There were 35 serious adverse events including seven deaths and one thromboembolism. None was related to IVIG. There were 56 and 48 moderate and severe AECOPD in the IVIG vs control groups. In patients with at least 80% treatment adherence, median time to first moderate or severe AECOPD was 275 vs 114 days, favoring the IVIG group (HR 0.76, 95% CI 0.3– 1.92). Conclusion: The study met feasibility criteria for recruitment and retention, but adherence was low. A trend toward more robust treatment efficacy in adherent patients supports further study, but future trials must address treatment adherence. Trial registration number: NCT0290038, registered 24 February 2016, https://clinicaltrials.gov/ct2/show/NCT02690038 and NCT03018652, registered January 12, 2017, https://clinicaltrials.gov/ct2/show/NCT03018652.
- Open Access
- 1 June 2021
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 13, 453-467
Case-Ascertainment Models to Identify Adults with Obstructive Sleep Apnea Using Health Administrative Data: Internal and External Validation
Background: There is limited evidence on whether obstructive sleep apnea (OSA) can be accurately identified using health administrative data. Study Design and Methods: We derived and validated a case-ascertainment model to identify OSA using linked provincial health administrative and clinical data from all consecutive adults who underwent a diagnostic sleep study (index date) at two large academic centers (Ontario, Canada) from 2007 to 2017. The presence of moderate/severe OSA (an apnea–hypopnea index≥ 15) was defined using clinical data. Of 39 candidate health administrative variables considered, 32 were tested. We used classification and regression tree (CART) methods to identify the most parsimonious models via cost-complexity pruning. Identified variables were also used to create parsimonious logistic regression models. All individuals with an estimated probability of 0.5 or greater using the predictive models were classified as having OSA. Results: The case-ascertainment models were derived and validated internally through bootstrapping on 5099 individuals from one center (33% moderate/severe OSA) and validated externally on 13,486 adults from the other (45% moderate/severe OSA). On the external cohort, parsimonious models demonstrated c-statistics of 0.75– 0.81, sensitivities of 59– 60%, specificities of 87– 88%, positive predictive values of 79%, negative predictive values of 73%, positive likelihood ratios (+LRs) of 4.5– 5.0 and –LRs of 0.5. Logistic models performed better than CART models (mean integrated calibration indices of 0.02– 0.03 and 0.06– 0.12, respectively). The best model included: sex, age, and hypertension at the index date, as well as an outpatient specialty physician visit for OSA, a repeated sleep study, and a positive airway pressure treatment claim within 1 year since the index date. Interpretation: Among adults who underwent a sleep study, case-ascertainment models for identifying moderate/severe OSA using health administrative data had relatively low sensitivity but high specificity and good discriminative ability. These findings could help study trends and outcomes of OSA individuals using routinely collected health care data.
- 1 June 2021
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 13, 453-467
Open AccessCase-Ascertainment Models to Identify Adults with Obstructive Sleep Apnea Using Health Administrative Data: Internal and External Validation
Background: There is limited evidence on whether obstructive sleep apnea (OSA) can be accurately identified using health administrative data. Study Design and Methods: We derived and validated a case-ascertainment model to identify OSA using linked provincial health administrative and clinical data from all consecutive adults who underwent a diagnostic sleep study (index date) at two large academic centers (Ontario, Canada) from 2007 to 2017. The presence of moderate/severe OSA (an apnea–hypopnea index≥ 15) was defined using clinical data. Of 39 candidate health administrative variables considered, 32 were tested. We used classification and regression tree (CART) methods to identify the most parsimonious models via cost-complexity pruning. Identified variables were also used to create parsimonious logistic regression models. All individuals with an estimated probability of 0.5 or greater using the predictive models were classified as having OSA. Results: The case-ascertainment models were derived and validated internally through bootstrapping on 5099 individuals from one center (33% moderate/severe OSA) and validated externally on 13,486 adults from the other (45% moderate/severe OSA). On the external cohort, parsimonious models demonstrated c-statistics of 0.75– 0.81, sensitivities of 59– 60%, specificities of 87– 88%, positive predictive values of 79%, negative predictive values of 73%, positive likelihood ratios (+LRs) of 4.5– 5.0 and –LRs of 0.5. Logistic models performed better than CART models (mean integrated calibration indices of 0.02– 0.03 and 0.06– 0.12, respectively). The best model included: sex, age, and hypertension at the index date, as well as an outpatient specialty physician visit for OSA, a repeated sleep study, and a positive airway pressure treatment claim within 1 year since the index date. Interpretation: Among adults who underwent a sleep study, case-ascertainment models for identifying moderate/severe OSA using health administrative data had relatively low sensitivity but high specificity and good discriminative ability. These findings could help study trends and outcomes of OSA individuals using routinely collected health care data.
- Open Access
- 10 November 2020
- Published by Taylor & Francis in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
- Vol. 6 (2) , 1-7
Operationalizing care in a hospital-based respirology clinic during a global pandemic
The novel coronavirus (SARS-CoV-2) pandemic has forced clinicians across Canada to abruptly adapt to a new reality of reduced contact with patients in ambulatory care settings. With minimal lead time, ambulatory clinics in Canada were required to adopt aggressive infection prevention and control measures while facing shortages of personal protective equipment and to enact strategies to urgently reorganize patient care. These adaptations included the conversion of ambulatory clinics to telephone or virtual care platforms. In 2015, the Public Health Agency of Canada (PHAC) published pandemic influenza preparedness guidelines highlighting the importance of pandemic preparedness planning in primary and ambulatory care settings, including clinic continuity planning and provisions for non in-person care. Despite these recommendations, hospital-based ambulatory clinics lacked formal strategic plans to adapt patient care processes during the SARS-CoV-2 outbreak. Thus, in a short time frame, clinics individually adapted their own patient care processes. This creates the potential for gaps in quality of medical care for patients across Canada. In this report, we describe the evolution and operationalization of care planning in our hospital-based respirology clinic, highlight the challenges faced, and make recommendations for respirology clinic adaptations based on available guidance. This process may be used as a foundation to guide future policy, discussion and guidelines for hospital-based respiratory care to ensure optimal preparedness during the next inevitable respiratory viral pandemic or possible worsening of the current pandemic.
- 10 November 2020
- Published by Taylor & Francis in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
- Vol. 6 (2) , 1-7
Open AccessOperationalizing care in a hospital-based respirology clinic during a global pandemic
The novel coronavirus (SARS-CoV-2) pandemic has forced clinicians across Canada to abruptly adapt to a new reality of reduced contact with patients in ambulatory care settings. With minimal lead time, ambulatory clinics in Canada were required to adopt aggressive infection prevention and control measures while facing shortages of personal protective equipment and to enact strategies to urgently reorganize patient care. These adaptations included the conversion of ambulatory clinics to telephone or virtual care platforms. In 2015, the Public Health Agency of Canada (PHAC) published pandemic influenza preparedness guidelines highlighting the importance of pandemic preparedness planning in primary and ambulatory care settings, including clinic continuity planning and provisions for non in-person care. Despite these recommendations, hospital-based ambulatory clinics lacked formal strategic plans to adapt patient care processes during the SARS-CoV-2 outbreak. Thus, in a short time frame, clinics individually adapted their own patient care processes. This creates the potential for gaps in quality of medical care for patients across Canada. In this report, we describe the evolution and operationalization of care planning in our hospital-based respirology clinic, highlight the challenges faced, and make recommendations for respirology clinic adaptations based on available guidance. This process may be used as a foundation to guide future policy, discussion and guidelines for hospital-based respiratory care to ensure optimal preparedness during the next inevitable respiratory viral pandemic or possible worsening of the current pandemic.